

parameter	unit	Baseline pre therapy		under Trastuzumab therapy: acute and chronic effect		p for MR 1 vs 2	p for MR 2 vs 3	p for MR 2 vs 4
		Baseline pre Anthracycline	Baseline pre Trastuzumab/Pertuzumab	after 1st Dose Trastuzumab/Pertuzumab	after 4th Dose Trastuzumab/Pertuzumab			
Trastuzumab-induced Cardiomyopathy (tCMP)								
T1 nativ	ms	1031.4 ±42.5	1041.2 ±28.6	1020.6 ±54.5	1044.7 ±39.1	0.345	0.398	0.345
T2	ms	51.5 ±2.6	49.6 ±1.7	54.0 ±3.7	51.8 ±3.0	0.018 *	0.028 *	0.249
synthetic ECV	%		25.0 ±1.2	24.8 ±4.1	26.2 ±2.3		0.753	0.116
Anthracyclin-induced Cardiomyopathy (aCMP)								
T1 nativ	ms	988.8 ±40.6	1085.9 ±44.5	1065.3 ±25.8	1049.4 ±28.1	0.109	0.109	0.109
T2	ms	47.6 ±2.8	50.0 ±1.4	47.7 ±0.8	52.1 ±5.8	0.180	0.180	0.180
synthetic ECV			26.2 ±2.5	25.6 ±2.5	24.1 ±2.6		0.285	0.109
No Cardiomyopathy (nCMP)								
T1 nativ	ms	1015.8 ±37.0	1040.6 ±41.0	1033.7 ±28.5	1030.5 ±67.9	0.279	0.679	0.501
T2	ms	49.1 ±4.9	51.7 ±3.9	51.6 ±3.3	49.4 ±3.5	0.064	0.958	0.056
synthetic ECV	%		25.3 ±2.3	26.0 ±3.6	25.5 ±2.4		0.397	0.638

Legend: Extracellular Volume (ECV)